scholarly journals Transcriptomic characterization of prurigo nodularis and the therapeutic response to nemolizumab

2021 ◽  
Author(s):  
Lam C. Tsoi ◽  
Feriel Hacini-Rachinel ◽  
Paul Fogel ◽  
Francois Rousseau ◽  
Xianying Xing ◽  
...  
Keyword(s):  
Therapeutic Response ◽  
Prurigo Nodularis

scholarly journals LB817 Transcriptomic characterization of Prurigo Nodularis and the therapeutic response to Nemolizumab.

2021 ◽  
Vol 141 (9) ◽  
pp. B27
Author(s):  
L. Tsoi ◽  
P. Fogel ◽  
X. Xing ◽  
M.T. Patrick ◽  
A.C. Billi ◽  
...  
Keyword(s):  
Therapeutic Response ◽  
Prurigo Nodularis

scholarly journals NIOSOMES: PRESENT SCENARIO AND FUTURE ASPECTS

2018 ◽  
Vol 8 (5) ◽  
pp. 35-43 ◽  
Author(s):  
Dhanvir Kaur ◽  
Sandeep Kumar
Keyword(s):  
Targeted Delivery ◽  
Drug Targeting ◽  
Therapeutic Response ◽  
The Body ◽  
Ionic Surfactant ◽  
Target Tissue ◽  
New Approach ◽  
Surfactant Vesicles ◽  
Subcellular Level

Drug targeting is a kind of phenomenon in which drug gets distributed in the body in such a manner that the drug interacts with the target tissue at a cellular or subcellular level to achieve a desired therapeutic response at a desire site without undesirable interactions at other sites. This can be achieved by modern methods of targeting the drug delivery system such as niosomes. Niosomes are the type of non-ionic surfactant vesicles, which are biodegradable, non-toxic, more stable and inexpensive, a new approach to liposomes. Their structure similar to liposome and hence they can represent alternative vesicular systems with respect to liposomes. The niosomes have the tendency to load different type of drugs. This review article represents the structure of niosome, advantages, disadvantages, the methods for  niosome preparation and characterization of pharmaceutical NSVs. Keywords:  Niosome, Cholesterol, Hydrophilic and Lipophilic drugs, Surfactant, Targeted delivery Bioavailability Improvement, Factors, Applications.

scholarly journals Dermoscopy Update: Review of its Extradiagnostic and Expanding Indications and Future Prospects

2019 ◽  
pp. 253-264
Author(s):  
Sidharth Sonthalia ◽  
Paola Pasquali ◽  
Mahima Agrawal ◽  
Poonam Sharma ◽  
Abhijeet K. Jha ◽  
...  
Keyword(s):  
Early Detection ◽  
Therapeutic Response ◽  
Response To Treatment ◽  
Clinicopathological Correlation ◽  
Future Prospects ◽  
Early Assessment ◽  
Treatment Protocols ◽  
New Generation ◽  
Selection Of

The technique of dermoscopy has come a long way since its inception for characterization of suspicious nevi for early detection of dysplastic changes in predisposed individuals. Not only has its scope expanded to aid in quick diagnosis of a majority of nonmelanocytic disorders of the skin, hair, and nails, but it is being rightfully exploited for a plethora of nondiagnostic uses. Its use in the diagnosis of various pigmentary, papulosquamous, and infectious disorders and disorders of the scalp and hair, nails, and mucosa bears testimony to the ongoing expansion of its protean indications across skin types. Dermoscopy has transformed the conventional approach to dermatological diagnosis from clinicopathological correlation to clinico-dermoscopic-pathological correlation. It aids in convincing an otherwise reluctant patient to agree to biopsy and guides the selection of optimum site for the same. Dermoscopic clues suggestive of stability or activity of the lesion and/or disease in various dermatoses are being accrued. Early assessment of therapeutic response to treatment is helpful for physicians, patients, and researchers conducting clinical studies. Aesthetic uses of dermoscopy are opulent and being explored. Dermoscopy has also provided the much-needed balancing act of interaction between practitioners and the new generation of patients. Last but not the least, dermoscopy has resulted in patients’ better understanding of their disorders and improved compliance with treatment protocols.

scholarly journals Insights into the Secretome of Mesenchymal Stem Cells and Its Potential Applications

2019 ◽  
Vol 20 (18) ◽  
pp. 4597 ◽  
Author(s):  
Sharon Eleuteri ◽  
Alessandra Fierabracci
Keyword(s):  
Stem Cells ◽  
Clinical Trials ◽  
Mesenchymal Stem Cells ◽  
Extracellular Vesicles ◽  
Therapeutic Response ◽  
Diagnostic Procedures ◽  
Clinical Applications ◽  
Potential Applications

Mesenchymal stem cells (MSCs) have regenerative, immunoregulatory properties and can be easily isolated and expanded in vitro. Despite being a powerful tool for clinical applications, they present limitations in terms of delivery, safety, and variability of therapeutic response. Interestingly, the MSC secretome composed by cytokines, chemokines, growth factors, proteins, and extracellular vesicles, could represent a valid alternative to their use. It is noteworthy that MSC-derived extracellular vesicles (MSC-EVs) have the same effect and could be advantageous compared to the parental cells because of their specific miRNAs load. MiRNAs could be useful both in diagnostic procedures such as “liquid biopsy” to identify early pathologies and in the therapeutic field. Not only are MSC-EVs’ preservation, transfer, and production easier, but their administration is also safer, hence some clinical trials are ongoing. However, much effort is required to improve the characterization of EVs to avoid artifacts and guarantee reproducibility of the studies.

Autism Clinical Trials: Biological and Medical Issues in Patient Selection and Treatment Response

CNS Spectrums ◽  
2004 ◽  
Vol 9 (1) ◽  
pp. 57-64 ◽  
Author(s):  
George M. Anderson ◽  
Andrew W. Zimmerman ◽  
Natacha Akshoomoff ◽  
Diane C. Chugani
Keyword(s):  
Therapeutic Response ◽  
Clinical Laboratory ◽  
Drug Action ◽  
Potential Utility ◽  
Patient Screening ◽  
Medical Issues ◽  
Potential Safety ◽  
Neurobiological Research ◽  
Metabolic Screening

ABSTRACTBiomedical measures are critical in the initial patient-screening and -selection phases of a clinical trial in autism and related disorders. These measures can also play an important role in the assessment and characterization of response and can provide an opportunity to study underlying etiologic and pathophysiologic processes. Thus, biomedical measures, including clinical laboratory analyses, metabolic screening, and chromosomal analysis, are used to screen for potential safety-related problems, to decrease biological and genetic heterogeneity, and to define subgroups. Neurobiological measures can be examined as possible predictors, modifiers or surrogates of therapeutic response, and adverse effects. Neurobiological research measures can also be used to study mechanisms and extent of drug action and to perform baseline and longitudinal investigations of possible pathophysiologic alterations. The potential utility and desirability of specific measures are considered and the general approach to choosing measures for incorporation is discussed.

scholarly journals Characterization of drug responses of mini patient-derived xenografts in mice for predicting cancer patient clinical therapeutic response

2018 ◽  
Vol 38 (1) ◽  
pp. 60 ◽  
Author(s):  
Feifei Zhang ◽  
Wenjie Wang ◽  
Yuan Long ◽  
Hui Liu ◽  
Jijun Cheng ◽  
...  
Keyword(s):  
Cancer Patient ◽  
Therapeutic Response ◽  
Drug Responses

scholarly journals Treatment of Recalcitrant Prurigo Nodularis with Dupilumab

2020 ◽  
Vol 4 (3) ◽  
pp. 279
Author(s):  
Matthew T Reynolds ◽  
Scott M Dinehart ◽  
Katlyn R Anderson ◽  
Joe Gorelick
Keyword(s):  
Atopic Dermatitis ◽  
Side Effects ◽  
Therapeutic Response ◽  
Rating Scale ◽  
Numerical Rating Scale ◽  
Biologic Agent ◽  
Dramatic Reduction ◽  
Prurigo Nodularis ◽  
Duration Of Therapy ◽  
Numerical Rating

Objectives: Prurigo nodularis (PN) is a disease of aberrant and recalcitrant itching which is difficult to effectively manage. There are no current FDA-approved therapies for PN.  The current topical and systemic medications used for this condition provide less than optimal efficacy for the majority of patients with this condition and often have unacceptable side effects.  We report 4 patients who were effectively treated with dupilumab (Dupixent) for the treatment of recalcitrant PN.Methods:  Four patients were treated successfully with dupilumab, a systemic biologic agent that is not immunosuppressive (Dupixent; Sanofi-Regeneron). Patients were treated with dupilumab monotherapy, without the use of other systemic immunosuppressing agents. The peak pruritus numerical rating scale (NRSi) was used to evaluate patients at weeks 0 and 4. Results: Dupilumab therapy results in a dramatic reduction in NRSi scores by week 4 and that result continues throughout the duration of therapy. This reduction in itch is seen with continuous therapy.Conclusion: Dupilumab therapy appears effective in reducing the overall itch severity in patients with PN. The usage of dupilumab as a monotherapy shows promise in the treatment of PN. The therapeutic response to dupilumab seen in PN suggests that the pathogenesis of PN may overlap with that of atopic dermatitis. 

Morphological Characterization of Mycobacteriophage R1

1974 ◽  
Vol 32 ◽  
pp. 254-255
Author(s):  
B. L. Soloff ◽  
T. A. Rado
Keyword(s):  
Carbon Source ◽  
Stationary Phase ◽  
Growth Phase ◽  
Minimal Medium ◽  
Morphological Characterization ◽  
Logarithmic Growth Phase ◽  
Complete Lysis ◽  
Lysogenic Culture ◽  
Logarithmic Growth

Mycobacteriophage R1 was originally isolated from a lysogenic culture of M. butyricum. The virus was propagated on a leucine-requiring derivative of M. smegmatis, 607 leu−, isolated by nitrosoguanidine mutagenesis of typestrain ATCC 607. Growth was accomplished in a minimal medium containing glycerol and glucose as carbon source and enriched by the addition of 80 μg/ ml L-leucine. Bacteria in early logarithmic growth phase were infected with virus at a multiplicity of 5, and incubated with aeration for 8 hours. The partially lysed suspension was diluted 1:10 in growth medium and incubated for a further 8 hours. This permitted stationary phase cells to re-enter logarithmic growth and resulted in complete lysis of the culture.

Sign in / Sign up

Export Citation Format

Share Document